Duyuru • Oct 24
Sharecare, Inc.(NasdaqGM:SHCR) dropped from NASDAQ Composite Index Sharecare, Inc. has been dropped from the NASDAQ Composite Index Recent Insider Transactions Derivative • Aug 23
Founder & Executive Chairman exercised options and sold US$245k worth of stock On the 16th of August, Jeffrey Arnold exercised options to acquire 177k shares at no cost and sold these for an average price of US$1.38 per share. This trade did not impact their existing holding. Since December 2023, Jeffrey's direct individual holding has increased from 8.52m shares to 10.27m. Company insiders have collectively sold US$3.9m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Aug 16
Chief Administrative Officer recently sold US$154k worth of stock On the 13th of August, Colin Daniel sold around 112k shares on-market at roughly US$1.38 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$208k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Aug 15
President & CFO notifies of intention to sell stock Justin Ferrero intends to sell 290k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of August. If the sale is conducted around the recent share price of US$1.38, it would amount to US$399k. Since September 2023, Justin's direct individual holding has increased from 938.87k shares to 1.92m. Company insiders have collectively sold US$2.5m more than they bought, via options and on-market transactions in the last 12 months. New Risk • Aug 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$61m net loss in 2 years). Shareholders have been diluted in the past year (3.9% increase in shares outstanding). Duyuru • Jun 22
Altaris, LLC entered into a definitive agreement to acquire Sharecare, Inc. (NasdaqGS:SHCR) for approximately $520 million. Altaris, LLC entered into a definitive agreement to acquire Sharecare, Inc. (NasdaqGS:SHCR) for approximately $520 million on June 21, 2024. The merger consideration is $1.43 per share. Upon the completion of the acquisition, Sharecare will become a privately held company and its common stock will no longer be listed on Nasdaq. A special committee of the Board of Directors of Sharecare, comprised solely of independent directors, carefully evaluated Altaris' proposal and alternatives thereto. Following this process, the Special Committee determined that the transaction is in the best interests of Sharecare and its stockholders, and acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction, and will recommend that the Company's stockholders approve both the adoption of the merger agreement and the transaction on the terms set forth in the merger agreement. The transaction is subject to approval of merger agreement by target board, approval of offer by target shareholders and the receipt of required regulatory approvals. The deal has been approved by the target board. The transaction is not subject to a financing condition. The transaction is expected to close in the second half of 2024. Houlihan Lokey and MTS Health Partners are acting as financial advisors to the Special Committee, and Wachtell, Lipton, Rosen & Katz is acting as legal advisor to the Special Committee. Kirkland & Ellis LLP is acting as legal advisor to Altaris. King & Spalding LLC is acting as legal advisor to Jeff Arnold. Price Target Changed • Jun 12
Price target decreased by 14% to US$1.50 Down from US$1.75, the current price target is an average from 2 analysts. New target price is 72% above last closing price of US$0.87. The company is forecast to post a net loss per share of US$0.38 next year compared to a net loss per share of US$0.36 last year. Duyuru • May 01
Sharecare, Inc., Annual General Meeting, Jun 13, 2024 Sharecare, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 US Eastern Standard Time. Agenda: To ?elect the three Class III nominees named in the accompanying Proxy Statement as Class III directors for a term expiring at the 2027 Annual Meeting of Stockholders; to approve an amendment to the Fourth Amended and Restated Certificate of Incorporation to authorize the Board of Directors to effect a reverse stock split of all of the outstanding shares of the common stock at a ratio in the range of 1-for-5 to 1-for-20, with the final decision of whether to proceed with the reverse stock split and the exact ratio and timing of the reverse split to be determined by the Board of Directors, in its discretion, following stockholder approval (if obtained), but no later than the first anniversary of the Annual Meeting, and a reduction in the authorized shares of the common stock; to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact other business. Duyuru • Apr 26
Sharecare, Inc. to Report Q1, 2024 Results on May 09, 2024 Sharecare, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Duyuru • Apr 21
Rosen Law Firm Files A Class Action Lawsuit Against Sharecare Inc Rosen Law Firm announced it has filed a class action lawsuit on behalf of purchasers of the securities of Sharecare Inc. between May 10, 2023 and March 28, 2024, both dates inclusive (the Class Period). A class action has already been filed. If it wish to serve as lead plaintiff, it must move the Court no later than June 18, 2024 in the securities class action first filed by the Firm. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Sharecare lacked adequate internal controls; and (2) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. Duyuru • Apr 07
Sharecare Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market On April 5, 2024, Sharecare, Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that the closing bid price for its common stock had been below $1.00 for 30 consecutive trading days and therefore the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Letter has no immediate impact on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Global Select Market under the symbol “SHCR,” and does not directly affect the Company’s business, operations or Securities and Exchange Commission reporting requirements. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including a reverse stock split, to regain compliance with the Bid Price Requirement. Under the Nasdaq Listing Rules, the Company has a period of 180 calendar days from the date of the Letter to regain compliance with the Bid Price Requirement (subject to additional time periods for which the Company may be eligible). Accordingly, the Company has until October 2, 2024 (the “Compliance Date”) to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 for a minimum of ten consecutive business days prior to the Compliance Date. Duyuru • Mar 29
Sharecare, Inc Appoints Nicole Torraco to its Board of Directors Sharecare, Inc. has appointed former Xerox executive Nicole Torraco to its Board of Directors as well as the previously referenced special committee. Further strengthening Sharecare’s commitment to effective governance and strategic direction, Torraco has extensive public company experience holding key executive roles in finance, M&A, and investment management over the last 25 years. Currently with K&B Global Consulting and a member of the Board of Directors of Pagaya Technologies Ltd., she previously was the President of FITTLE, the financing arm of Xerox Corporation, which she grew into a global specialty finance business. She also served on Xerox’s Executive Committee and Enterprise Risk Management Committee and was a Director on the Board of Xerox Financial Services LLC. Prior to leading FITTLE, Torraco served as Xerox’s Chief Strategy and M&A Officer. Duyuru • Mar 13
Sharecare, Inc. announced delayed annual 10-K filing On 03/12/2024, Sharecare, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Feb 23
Sharecare, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Sharecare, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024 Recent Insider Transactions Derivative • Feb 22
Founder & Executive Chairman exercised options and sold US$216k worth of stock On the 15th of February, Jeffrey Arnold exercised options to acquire 202k shares at no cost and sold these for an average price of US$1.07 per share. This trade did not impact their existing holding. Since June 2023, Jeffrey's direct individual holding has increased from 8.47m shares to 9.17m. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 11
Founder & Executive Chairman exercised options and sold US$660k worth of stock On the 6th of February, Jeffrey Arnold exercised options to acquire 606k shares at no cost and sold these for an average price of US$1.09 per share. This trade did not impact their existing holding. Since June 2023, Jeffrey's direct individual holding has increased from 8.47m shares to 8.52m. Company insiders have collectively sold US$1.9m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Nov 12
Price target decreased by 10.0% to US$3.00 Down from US$3.33, the current price target is an average from 3 analysts. New target price is 194% above last closing price of US$1.02. The company is forecast to post a net loss per share of US$0.33 next year compared to a net loss per share of US$0.34 last year. Reported Earnings • Nov 10
Third quarter 2023 earnings released: US$0.07 loss per share (vs US$0.078 loss in 3Q 2022) Third quarter 2023 results: US$0.07 loss per share (improved from US$0.078 loss in 3Q 2022). Revenue: US$113.3m (down 1.1% from 3Q 2022). Net loss: US$24.5m (loss narrowed 11% from 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Duyuru • Oct 13
Sharecare, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Sharecare, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 09, 2023 New Risk • Oct 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Major Estimate Revision • Aug 31
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.30 to -US$0.335 per share. Revenue forecast unchanged at US$457.3m. Healthcare Services industry in the US expected to see average net income growth of 4.3% next year. Consensus price target of US$3.33 unchanged from last update. Share price rose 10% to US$0.95 over the past week. Reported Earnings • Aug 10
Second quarter 2023 earnings: EPS misses analyst expectations Second quarter 2023 results: US$0.099 loss per share (further deteriorated from US$0.084 loss in 2Q 2022). Revenue: US$110.4m (up 6.3% from 2Q 2022). Net loss: US$35.1m (loss widened 21% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US. Duyuru • Aug 10
Sharecare, Inc. Provides Revenue Guidance for the Third Quarter Ending September 30, 2023 and Fiscal Year Ending December 31, 2023 Sharecare, Inc. provided revenue guidance for the Third Quarter ending September 30, 2023 and Fiscal year ending December 31, 2023. For the three months ending September 30, 2023, Company expects Revenue in the range of $111 million to $113 million.For the twelve months ending December 31, 2023, the Company continues to expect Revenue in the range of $452.5 million to $460 million. Duyuru • Aug 02
Sharecare Expands Suite of Customer Activation and Management Solutions to Support Patient Education and Improve the Care Journey Sharecare announced five new solutions designed to engage, educate, and activate patients to better understand the conditions impacting their lives and take meaningful actions towards improving their health and well-being. With extensive digital capabilities and a zero party- database of over 100 million, Sharecare's new customer activation and management solutions for life sciences companies build on emerging consumer trends to reach the right people at the right time with contextually relevant, actionable information they want and can trust. Available to reserve now for fourth quarter 2023 and 2024 campaigns, the newest customer activation and management solutions from Sharecare include: Populatioion Perspective -- Complementing Sharecare's robust catalog of award-winng health equitity content, this solution informs, inspires, and connects minority populations with resources to help them find culturally competent, condition-specific care as well as actionable advice. Life Unscripted -- Featuring relatable and candid first-person advice from real patients living with a specific condition, this solution showcases a variety of content to engage and support individuals on their personal health journeys, including animated videos; curated lists of "go-to" resources; day-in-the-life video diaries; and interactive chesheets with actionable tips. Oncology Roadmap -- Created to support patients and their caregivers, this solution helps people navigate the cancer treatment journey by delivering clinician perspectives on managing care; conversation guides to support discussions with healthcare providers and loved ones; information about the types of specialists that may comprise one's care team; and direct access to medically vetted, condition-specific articles. Myth-information -- Designed to drive and elevate productive provider-patient discussions, this tool utilizes an interactive and easy-to-understand quiz format to help individuals assess their knowledge about their condition, while simultaneously dispelling common myths and mis information. Point-of-Care Network -- Sharecare's partners can enhance their campaigns and strategic planning through a new targeted point-of-care solution available across 1,100 dedicated on-site testing and diagnostic facilities -- which reach over 1.3 million patients per month and engage over 160 million patients annually, many of whom are managing a specific condition. Duyuru • Jul 23
Sharecare, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Sharecare, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023 Duyuru • Jun 01
Sharecare, Inc. (NasdaqGS:SHCR) announces an Equity Buyback for $50 million worth of its shares. Sharecare, Inc. (NasdaqGS:SHCR) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common shares. The company expects to fund the repurchase program from its existing cash and cash equivalents. The program will be valid for 12 months. As at March 31, 2023, the company had 356,289,293 issued and outstanding shares. Major Estimate Revision • May 24
Consensus EPS estimates fall by 16% The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -US$0.325 per share expected, vs -US$0.28 per share profit forecast previously. Revenue forecast reaffirmed at US$458.7m. Healthcare Services industry in the US expected to see average net income growth of 9.2% next year. Consensus price target of US$3.33 unchanged from last update. Share price rose 3.7% to US$1.41 over the past week. Major Estimate Revision • May 17
Consensus EPS estimates fall by 61% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.18 to -US$0.29 per share. Revenue forecast unchanged at US$458.2m. Healthcare Services industry in the US expected to see average net income growth of 3.8% next year. Consensus price target of US$3.33 unchanged from last update. Share price fell 9.3% to US$1.36 over the past week. Reported Earnings • May 10
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2023 results: US$0.098 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$116.3m (up 16% from 1Q 2022). Net loss: US$34.7m (loss narrowed 9.3% from 1Q 2022). Revenue exceeded analyst estimates by 4.9%. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US. Recent Insider Transactions Derivative • Apr 11
Key Executive exercised options and sold US$94k worth of stock On the 5th of April, Jaffry Mohammed exercised options to acquire 64k shares at no cost and sold these for an average price of US$1.45 per share. This trade did not impact their existing holding. As of today, Jaffry currently holds no shares directly. Company insiders have collectively sold US$279k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Mar 31
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$0.34 loss per share (further deteriorated from US$0.30 loss in FY 2021). Revenue: US$442.4m (up 7.2% from FY 2021). Net loss: US$118.7m (loss widened 40% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.5%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in the US. Duyuru • Jan 27
Sharecare Launches VR Program to Improve Well-Being of American Workforce and Bring Innovation to Exercise Sharecare announced the launch of Get Active, a new program to help employers encourage exercise among their workforces in a fun, approachable, and accessible way, using the immersive power of virtual reality (VR). In a pilot with its customer Lennar Corporation, one of the nation's leading homebuilders, Sharecare's Get Active program for Meta Quest 2 yielded strong results for both healthy and high-risk Associates. In addition to the immediate health benefits of physical activity – including improved sleep quality and reduced anxiety and blood pressure – it can help reduce and prevent the risk of chronic disease. Regular exercise also has been shown to reverse pre-diabetes, which according to the CDC, more than 1 in 3 American adults have; and, of those with prediabetes, more than 80% are unaware they have it. Duyuru • Jan 19
Sharecare Launches Virtual Model of Its Medicare-Reimbursable Cardiac Rehabilitation Program, Ornish Lifestyle Medicine Sharecare announced Ornish Lifestyle Medicine by Sharecare, the company's Intensive Cardiac Rehabilitation (ICR) program, is now available through a virtual delivery model. Reimbursable through Medicare and many commercial plans, Ornish Lifestyle Medicine by Sharecare is the first and only ICR program scientifically proven in randomized controlled trials to often reverse the progression of coronary heart disease and many other chronic conditions, without drugs or surgery. To date, Ornish Lifestyle Medicine by Sharecare has empowered patients to manage, navigate, and improve their cardiac health through a center-based, in-person offering. By enabling patients to participate remotely in the Ornish program, Sharecare is removing barriers to access for eligible individuals, regardless of their location, which serves to not only improve health outcomes but also advance health equity. Further, in initial cohorts, the newly available virtual delivery model of the Ornish program yielded 99% completion rates among participants. Ornish Lifestyle Medicine by Sharecare is comprised of four key pillars – nutrition, fitness, stress management, and love and support – and provides each program cohort with a dedicated, certified team of clinical experts, including a physician, nurse, registered dietitian, exercise physiologist, group support facilitator, and stress management specialist. By using lifestyle changes as less invasive and often more effective treatment options than medication or surgical interventions alone, the Ornish program empowers individuals to improve their heart's function. Over 13,000 patients have completed the Ornish ICR program from Sharecare. On average, these graduates experienced 72% reduction in angina (chest pain), 21.1% reduction in LDL-cholesterol in those already on maximal medical therapy, 4.6% reduction in BMI, 6% reduction in hemoglobin A1C, 45% improvement in exercise capacity, and 48% improvement in depression scores; and were 45% less likely to experience a major cardiac event in the 12 months following program completion. Price Target Changed • Jan 13
Price target increased to US$3.50 Up from US$3.15, the current price target is an average from 3 analysts. New target price is 60% above last closing price of US$2.19. Stock is down 39% over the past year. The company is forecast to post a net loss per share of US$0.34 next year compared to a net loss per share of US$0.30 last year. Duyuru • Jan 12
Sharecare, Inc. Appoints Brent Layton to Its Board of Directors and Audit Committee Sharecare, Inc. has appointed Brent Layton to its board of directors and Audit Committee, effective January 11, 2023. Mr. Layton has more than 30 years of experience with increasing responsibility in the healthcare and public policy sectors, with extensive expertise in creating, scaling, and operating business in a highly regulated environment. Currently serving as senior advisor to the CEO at Centene Corporation, Mr. Layton plays a pivotal role in developing and expanding key strategic partnerships for the company and driving its business development strategy. Previously, Mr. Layton served as president and chief operating officer for Centene Corporation where he oversaw the company's healthcare offerings, including 31 State Medicaid Health plans, the nation's largest Exchange provider, Ambetter, and the WellCare brand of Medicare products, and was a member of the Office of the CEO. Since joining Centene in 2006, he has overseen the development and implementation of new health plans in more than 25 states, provided strategic guidance to state governments to help them develop effective Medicaid solutions, and developed new business contracting with providers and health systems where he led the company's effort in value-based purchasing. Reported Earnings • Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: US$0.078 loss per share (improved from US$0.13 loss in 3Q 2021). Revenue: US$114.6m (up 8.5% from 3Q 2021). Net loss: US$27.4m (loss narrowed 37% from 3Q 2021). Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) missed analyst estimates by 9.1%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US. Reported Earnings • Nov 13
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: US$0.078 loss per share (improved from US$0.13 loss in 3Q 2021). Revenue: US$114.6m (up 8.5% from 3Q 2021). Net loss: US$27.4m (loss narrowed 37% from 3Q 2021). Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) missed analyst estimates by 9.1%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US. Price Target Changed • Oct 05
Price target decreased to US$3.40 Down from US$4.00, the current price target is an average from 4 analysts. New target price is 70% above last closing price of US$2.00. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$0.30 last year. Major Estimate Revision • Aug 17
Consensus EPS estimates fall by 69% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$472.9m to US$437.6m. Losses expected to increase from US$0.21 per share to US$0.35. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$4.63 to US$4.25. Share price fell 3.8% to US$1.76 over the past week. Reported Earnings • Aug 11
Second quarter 2022 earnings: EPS misses analyst expectations Second quarter 2022 results: US$0.084 loss per share. Revenue: US$103.8m (up 5.4% from 2Q 2021). Net loss: US$29.0m (flat on 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%. Over the next year, revenue is forecast to grow 16%, compared to a 19% growth forecast for the industry in the US. Major Estimate Revision • May 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.02 to -US$0.20 per share. Revenue forecast unchanged at US$476.2m. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$6.67 to US$6.17. Share price rose 37% to US$2.69 over the past week. Reported Earnings • May 13
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: US$0.11 loss per share. Revenue: US$100.7m (up 12% from 1Q 2021). Net loss: US$38.2m (loss widened 20% from 1Q 2021). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 267%. Over the next year, revenue is forecast to grow 17%, compared to a 17% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target decreased to US$6.67 Down from US$10.50, the current price target is an average from 3 analysts. New target price is 146% above last closing price of US$2.71. Stock is down 73% over the past year. The company is forecast to post earnings per share of US$0.04 next year compared to a net loss per share of US$0.30 last year. Breakeven Date Change • Apr 27
Forecast breakeven date pushed back to 2023 The 3 analysts covering Sharecare previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 91% to 2022. The company is expected to make a profit of US$23.8m in 2023. Average annual earnings growth of 140% is required to achieve expected profit on schedule. Major Estimate Revision • Apr 07
Consensus revenue estimates fall by 12% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$539.6m to US$477.2m. Forecast loss of -US$0.02, down from profit of US$0.05 per share profit previously. Healthcare Services industry in the US expected to see average net income growth of 21% next year. Consensus price target down from US$10.50 to US$6.67. Share price fell 4.5% to US$2.36 over the past week. Reported Earnings • Apr 01
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: US$0.30 loss per share. Revenue: US$412.8m (up 26% from FY 2020). Net loss: US$85.0m (loss widened 40% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 49%. Over the next year, revenue is forecast to grow 18%, compared to a 22% growth forecast for the industry in the US. Price Target Changed • Feb 12
Price target decreased to US$10.50 Down from US$13.00, the current price target is an average from 2 analysts. New target price is 232% above last closing price of US$3.16. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$28.48 last year. Breakeven Date Change • Aug 18
No longer forecast to breakeven The 2 analysts covering Sharecare no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$20.8m in 2023. New consensus forecast suggests the company will make a loss of US$3.48m in 2023. Executive Departure • Jul 13
Director Bradley Karro has left the company On the 1st of July, Bradley Karro's tenure as Director ended. We don't have any record of a personal shareholding under Bradley's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director James Scott English has left the company On the 1st of July, James Scott English's tenure as Director ended. We don't have any record of a personal shareholding under James Scott's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director Brian Pieninck has left the company On the 1st of July, Brian Pieninck's tenure as Director ended. We don't have any record of a personal shareholding under Brian's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director Lauren Brueggen has left the company On the 1st of July, Lauren Brueggen's tenure as Director ended. We don't have any record of a personal shareholding under Lauren's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director Kai-Shing Tao has left the company On the 1st of July, Kai-Shing Tao's tenure as Director ended. We don't have any record of a personal shareholding under Kai-Shing's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Co-Founder, Partner & Director Mehmet Oz has left the company On the 1st of July, Mehmet Oz's tenure as Co-Founder, Partner & Director ended. We don't have any record of a personal shareholding under Mehmet's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director Dan Fox has left the company On the 1st of July, Dan Fox's tenure as Director ended. We don't have any record of a personal shareholding under Dan's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 13
Director Mark Mastrov has left the company On the 1st of July, Mark Mastrov's tenure as Director ended after 10.1 years in the role. We don't have any record of a personal shareholding under Mark's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.